Demographics of female adult CF lung transplant recipients
| Transplanted without HPV complications (n=22) n (%) | Transplanted with HPV complications (n=12) n (%) | |
| CF-related factors | ||
| Genotype, n (%) | ||
| ΔF508 homozygous | 11 (50) | 5 (42) |
| ΔF508 heterozygous | 7 (32) | 7 (58) |
| Other | 4 (18) | 0 (0) |
| CF comorbidities, n (%) | ||
| Pancreatic insufficiency | 19 (86) | 11 (92) |
| CF liver disease | 4 (18) | 1 (8) |
| Gastrointestinal reflux disease | 10 (45) | 6 (50) |
| Distal intestinal obstruction syndrome | 10 (45) | 7 (58) |
| CF arthropathy | 5 (23) | 0 (0) |
| Sinus disease (polyps or nasal congestion) | 11 (50) | 7 (58) |
| Pretransplant factors | ||
| Age at the time of transplant/cohort inclusion, years, median (IQR) | 29.7 (23.7–33.9) | 26.7 (23.5–32.3) |
| Body mass index at the time of transplant (kg/m2), median (IQR) | 20.6 (18.2–21.1) | 19.8 (18.2–20.9) |
| FEV1 predicted at the time of transplant, median (IQR) | 24.8 (17.1–29.3) | 26.5 (22.0–31.5) |
| CF-related diabetes pretransplant | 7 (32) | 4 (33) |
| Chronic Pseudomonas aeruginosa infection (%) | 20 (91) | 9 (75) |
| Post-transplant factors | ||
| CF-related diabetes post-transplant | 12 (55) | 7 (58) |
| CMV status, n (%) | ||
| Donor +, Recipient − | 6 (27) | 4 (33) |
| Donor +, Recipient + | 9 (41) | 5 (42) |
| Other | 7 (32) | 3 (25) |
| Maintenance immunosuppression, n (%)* | ||
| Tacrolimus | 17 (77) | 11 (92) |
| Corticosteroids | 22 (100) | 12 (100) |
| Mycophenolate | 19 (86) | 10 (83) |
| Azathioprine | 3 (14) | 1 (8) |
| Sirolimus | 2 (9) | 1 (8) |
| Ciclosporin | 1 (5) | 0 (0) |
| Aspergillus infection, n (%) | 5 (23) | 2 (17) |
| Patients with ≥1 acute cellular rejection episode, n (%) | 12 (55) | 5 (42) |
| BOS-free survival, without BOS, n (%)† | ||
| 5 years | 9 (60) | 5 (50) |
| 10 years | 4 (50) | 2 (33) |
| Overall survival, alive, n (%) | ||
| 5 years | 15 (68) | 10 (83) |
| 10 years | 8 (36) | 6 (50) |
*Patients were often on multiple drug regimens and thus the numbers are greater than the total sum of patients. Immunosuppression regimen at the time of abnormal first pap smear is reported.
†Numbers calculated from the total population of patients alive at the time of assessment.
BOS, bronchiolitis obliterans syndrome; CF, cystic fibrosis; CMV, cytomegalovirus; HPV, human papillomavirus.